Pulse.

a daily field guide to health research that matters

◆ Console

‹ back to Sun · 1 Nov 2026

Deep-dive briefing

Sun · 1 Nov 2026

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

Phase 2 Evidence and Impact Analysis


Article 1 — Puccini et al. — PROSIT study (PMID: 42966319)

Immune Exclusion signature in stage II colon cancer | Prospective clinical-trial correlative transcriptomic study

Dimension Score Rationale
Scientific Novelty 7 IE signature predicting DFS independent of MSI/sidedness is a meaningful refinement in a molecularly crowded space; not entirely new territory but adds prospective trial-linked evidence
Clinical Relevance 7 Stage II CRC adjuvant decisions are a persistent clinical dilemma; an immune signature tied to DFS could reshape chemotherapy selection
Population Reach 6 Stage II CRC is common (~130,000 new US cases/year); "high-risk" subset narrows reach but is still substantial
Implementation Speed 5 Transcriptomic profiling requires lab infrastructure, regulatory clearance, and prospective validation before clinical deployment
Evidence Strength 7 Prospective, trial-embedded design (TOSCA phase III) is a strong methodological foundation; abstract-only access limits full confidence

Key quantitative result: IE signature associated with significantly shorter DFS; adjusted for MSI status and tumor sidedness — effect size not extractable from abstract. Validation status: Embedded in a phase III trial cohort; not independently externally replicated yet. Main limitation: Abstract-only; sample size unreported; survival follow-up duration unclear; single-country/trial cohort limits generalizability. Equity implications: Transcriptomic profiling costs and infrastructure inequities could limit access for patients in lower-resource settings; rural patients and underserved systems may face delays. Evidence Maturity: Validated ✓ (confirmed — prospective trial-embedded design is appropriate for this label)


Article 2 — Chen et al. — FFL in diabetic kidney disease (PMID: 42966155)

Fucoidan/fucoxanthin/l-carnitine in DKD | Proof-of-concept RCT + preclinical

Dimension Score Rationale
Scientific Novelty 6 Marine-derived compound combination is novel in DKD; l-carnitine and fucoidans individually studied, but this triple combination is less well characterized
Clinical Relevance 6 DKD is a major unmet need; LDL reduction and eGFR preservation are meaningful endpoints, but proof-of-concept size and 12-week horizon limit impact
Population Reach 7 Diabetic kidney disease affects ~40% of people with diabetes globally — enormous population
Implementation Speed 4 Dietary supplements could deploy rapidly in principle, but regulatory pathway for therapeutic claims and larger RCTs needed first
Evidence Strength 5 Proof-of-concept RCT is encouraging but underpowered for clinical conclusions; mixed species design adds uncertainty

Key quantitative result: LDL GMR 0.85 (95% CI: 0.76–0.95; p<0.01); up to 24.28% LDL reduction in dyslipidemics. Validation status: No external replication; single proof-of-concept trial. Main limitation: Small, short-duration, proof-of-concept only; sample size not reported in abstract; mixed-species design; 12 weeks insufficient to assess hard renal outcomes. Equity implications: If effective, supplement-based therapies could be lower-cost; however, unclear pricing, formulation availability, and absence of data in non-Asian populations limits generalizability. Evidence Maturity: Revised → Exploratory (label of "Validated" overstates a proof-of-concept RCT)


Article 3 — Kajiura et al. — Japan C-CAT CGP reference (PMID: 42965781)

Nationwide CGP alteration frequencies in Japan | Retrospective cohort

Dimension Score Rationale
Scientific Novelty 5 Descriptive reference dataset; valuable infrastructure but not a discovery study
Clinical Relevance 5 Provides population-level reference frequencies useful for interpreting CGP results; indirect clinical utility
Population Reach 6 Applicable across cancer types tested in Japan's CGP pathway; relevant internationally as a comparator dataset
Implementation Speed 6 Reference data is immediately usable by clinicians interpreting CGP reports
Evidence Strength 6 Nationwide registry gives large-scale coverage; retrospective and abstract-only limits full appraisal

Key quantitative result: Descriptive alteration frequencies; no comparative effect size reported. Validation status: Single-country descriptive; no external validation applicable. Main limitation: Japan-specific; ethnic/genomic differences limit direct applicability to non-Japanese populations; non-ICI-specific scope narrows clinical utility focus. Equity implications: Strengthens genomic medicine infrastructure in Japan; less relevant to populations in settings without CGP access; could serve as a model for other national programs. Evidence Maturity: Validated ✓ (appropriate for descriptive reference data)


Article 4 — Massalha et al. — Local ablation in NSCLC oligoprogression (PMID: 42965526)

LAT during immunotherapy for oligoprogressive mNSCLC | Systematic review + meta-analysis

Dimension Score Rationale
Scientific Novelty 6 Strategy of continuing IO + adding local ablation is not conceptually new, but this meta-analysis consolidates evidence and refines the signal
Clinical Relevance 7 Oligoprogression during IO is a daily clinical challenge; even modest PFS/OS gains are practice-relevant in mNSCLC
Population Reach 7 NSCLC is the most common cause of cancer death globally; IO-treated patients with oligoprogression represent a large and growing subgroup
Implementation Speed 6 Local ablative treatments (SBRT, RFA) are already in clinical use; adoption could be rapid if guideline-supported
Evidence Strength 5 Meta-analysis based predominantly on observational, low-certainty evidence; lacks RCT-level support

Key quantitative result: Improved PFS and OS associated with LAT; exact HR/CI not extractable from abstract. Validation status: Synthesizes existing literature; no new primary data; evidence base is observational. Main limitation: Low-certainty, predominantly observational evidence base; publication bias risk; heterogeneity in ablative modalities, IO agents, and patient selection likely high. Equity implications: Ablative procedures require specialized equipment and expertise; access inequities in low-resource settings and rural areas could limit benefit. Evidence Maturity: Revised → Exploratory (low-certainty observational synthesis does not warrant "Validated")


Article 5 — John et al. — Gut microbiome in CHD newborns (PMID: 42966652)

SES and feeding on gut microbiome in CHD neonates | Prospective matched cohort (secondary analysis)

Dimension Score Rationale
Scientific Novelty 6 Intersection of CHD, SES, gut microbiome, and feeding is relatively novel and clinically meaningful
Clinical Relevance 5 Identifies modifiable factors (feeding method) but does not yet link microbiome changes to outcomes
Population Reach 4 CHD affects ~1% of births; relevant but rare disease context
Implementation Speed 5 Breastfeeding promotion and feeding tube minimization are feasible; SES interventions are complex
Evidence Strength 5 Prospective matched design is solid for this field; secondary analysis limits causal inference

Key quantitative result: Feeding tubes, formula, aortic cross-clamp time, and SES associated with reduced microbiome diversity; effect sizes not reported in abstract. Main limitation: Secondary analysis; causality between microbiome disruption and outcomes not established; small population. Equity implications: SES explicitly modeled as a predictor — directly highlights health equity dimensions; findings particularly relevant to lower-income families. Evidence Maturity: Exploratory ✓


Article 6 — Haber et al. — Low-dose vs standard-dose alteplase in PE (PMID: 42966650)

Alteplase dosing in high-risk PE | Retrospective cohort

Dimension Score Rationale
Scientific Novelty 5 Low-dose thrombolysis is an active research question; retrospective data adds to but doesn't resolve the debate
Clinical Relevance 7 High-risk PE carries ~30% mortality; if low-dose is non-inferior with less bleeding, practice implications are immediate
Population Reach 6 High-risk PE is an emergency medicine and critical care staple; affects tens of thousands annually in the US
Implementation Speed 6 Alteplase is already available; dose adjustment is operationally simple if evidence supports it
Evidence Strength 4 Retrospective cohort; confounding by indication likely; high mortality in both groups (45–48%) suggests very sick patients; small sample inferred

Key quantitative result: In-hospital mortality 48% (low-dose) vs. 45% (standard-dose), p=0.81 — no significant difference detected, but study likely underpowered. Main limitation: Retrospective design; no bleeding outcomes reported in abstract; likely underpowered; selection bias for which patients received low vs. standard dose. Equity implications: Simpler/safer dosing protocols could improve care in lower-resourced settings; no equity analysis reported. Evidence Maturity: Exploratory ✓


Article 7 — Greathouse et al. — Dysphagia and high-flow nasal cannula (PMID: 42966646)

HFNC and dysphagia risk in ICU | Retrospective chart audit

Dimension Score Rationale
Scientific Novelty 4 Dysphagia in HFNC patients has been raised before; chart audit adds quantification but limited new insight
Clinical Relevance 6 Dysphagia is underrecognized in ICU; association with prolonged stay and intubation is clinically actionable
Population Reach 5 HFNC use is widespread in ICUs globally; dysphagia screening is widely applicable
Implementation Speed 7 Swallowing screening is low-cost and implementable quickly
Evidence Strength 3 Retrospective chart audit is among the weakest designs; no causal inference possible

Main limitation: Retrospective audit; causality unclear (dysphagia may predate HFNC or result from underlying illness rather than HFNC itself). Equity implications: ICU-acquired complications disproportionately affect vulnerable patients; dysphagia screening protocols need equity-conscious implementation. Evidence Maturity: Exploratory ✓


Article 8 — Adams et al. — Hospital-acquired anemia in ICU (PMID: 42966645)

HAA prevalence in Florida ICU | Retrospective medical record review

Dimension Score Rationale
Scientific Novelty 3 HAA from phlebotomy is well-established; single-center descriptive data adds limited new knowledge
Clinical Relevance 5 Blood conservation is actionable; knowing local prevalence can drive QI initiatives
Population Reach 5 HAA is ubiquitous in ICUs; but single-center Florida data limits generalizability
Implementation Speed 6 Blood conservation protocols (smaller draw volumes, bundled testing) are adoptable now
Evidence Strength 3 Retrospective medical record review; causality not established; single-center

Main limitation: Single-center; causality between phlebotomy and anemia not measured; no outcome data linking HAA to mortality/morbidity. Equity implications: Marginalized patients with less healthcare advocacy may undergo more unnecessary testing; equity implications of blood loss in vulnerable populations. Evidence Maturity: Exploratory ✓


Article 9 — Choi & Lee — KMT2A-r AML transcriptomics (PMID: 42966630)

Kinase inhibitor sensitivity in KMT2A-rearranged AML | Retrospective transcriptomic analysis

Dimension Score Rationale
Scientific Novelty 6 KMT2A-rearranged AML is mechanistically distinct; linking transcriptomic state to kinase inhibitor sensitivity beyond FLT3 is a meaningful contribution
Clinical Relevance 5 Potential to refine drug selection in a high-risk AML subset; preclinical stage
Population Reach 4 KMT2A-r AML ~5–10% of adult AML; meaningful unmet need despite small absolute numbers
Implementation Speed 3 Transcriptomic profiling for drug sensitivity is not standard of care; long path to clinical application
Evidence Strength 4 Retrospective transcriptomic analysis; medium classification confidence; no prospective validation

Key quantitative result: Not reported in abstract. Main limitation: Retrospective, computational — not validated prospectively; medium-confidence classification; abstract-only. Equity implications: AML disproportionately affects older adults; precision medicine tools may initially concentrate in academic centers. Evidence Maturity: Revised → Exploratory (appropriate)


Article 10 — Goldman — DSRCT therapeutic target atlas (PMID: 42966626) 🟡

Therapeutic targets in desmoplastic small round cell tumor | Multi-cohort transcriptomic study

Dimension Score Rationale
Scientific Novelty 7 DSRCT is an ultra-rare cancer with virtually no effective therapies; a systematic route-aware target atlas is a meaningful foundational resource
Clinical Relevance 5 Identifies candidates; RNA expression alone does not confirm druggability — but for a disease with no good options, even this is significant
Population Reach 3 Ultra-rare (~200–300 US cases/year); high relative unmet need justifies attention despite small absolute numbers
Implementation Speed 3 Requires extensive preclinical and clinical follow-up; no near-term translation expected
Evidence Strength 5 Two-cohort design provides some reproducibility; 61 patients is reasonable for this ultra-rare disease; RNA-only limits conclusions

Key quantitative result: Candidate targets detected in all 61 patients across two cohorts; specific targets not named in abstract. Main limitation: RNA-level only; therapeutic accessibility, efficacy, and safety explicitly unconfirmed; small N inherent to disease rarity. Equity implications: DSRCT predominantly affects young males; often diagnosed late; rare disease equity concerns around diagnosis delays and access to clinical trials. Evidence Maturity: Exploratory ✓ (relative to rare disease population, this is meaningful early work)


Article 11 — Vrancianu et al. — Raman spectroscopy for glioma (PMID: 42966518)

Raman spectroscopy in glioma diagnostics | Systematic review

Dimension Score Rationale
Scientific Novelty 6 Raman spectroscopy for intraoperative/diagnostic glioma classification is an emerging modality; systematic review adds clarity
Clinical Relevance 5 Glioma diagnosis and grading are critical; technology shows promise but is far from standard use
Population Reach 4 Glioma ~25,000 new US cases/year; relevant but not common
Implementation Speed 3 Substantial methodological standardization required before clinical deployment
Evidence Strength 5 Systematic review; limited by heterogeneous included studies; no pooled quantitative estimate possible

Main limitation: Heterogeneous protocols; no external validation; predominantly retrospective single-center primary studies. Equity implications: Specialized optical equipment; likely to concentrate in well-resourced neurosurgical centers initially. Evidence Maturity: Exploratory ✓


Article 12 — Yang et al. — GLP-1 RAs in MASLD cardiovascular outcomes (PMID: 42966342)

GLP-1 agonists and CV outcomes in MASLD | Propensity-matched cohort + mouse study

Dimension Score Rationale
Scientific Novelty 6 GLP-1 benefit in MASLD with cardiac endpoints is an active area; propensity-matched + mechanistic animal data adds value
Clinical Relevance 6 MASLD + CV risk is a major clinical challenge; GLP-1 agonists are widely used — this adds a specific MASLD signal
Population Reach 8 MASLD affects ~25–30% of adults globally; CV risk in this population is enormous
Implementation Speed 5 GLP-1 agonists are already prescribed; specific MASLD indication would require label expansion and guideline updates
Evidence Strength 5 Propensity matching reduces but doesn't eliminate confounding; mixed-species adds mechanistic insight but not clinical certainty; abstract-only

Key quantitative result: Not quantitatively specified in abstract; described as improvement in cardiac functional indices and molecular remodeling. Main limitation: Observational design; mouse mechanistic data not directly translatable; abstract-only access. Equity implications: GLP-1 agonists are expensive; MASLD disproportionately affects lower-income populations with less drug access. Evidence Maturity: Revised → Exploratory (propensity-matched observational + preclinical does not meet "Validated")


Article 13 — Khan et al. — HTN+hyperlipidemia mortality trends (PMID: 42966230)

US hypertension-hyperlipidemia mortality projections | Ecological study

Dimension Score Rationale
Scientific Novelty 4 Trend data from CDC WONDER is a known methodology; projections to 2035 add modest value
Clinical Relevance 5 Policy-relevant but does not change individual patient management directly
Population Reach 9 Hypertension affects ~50% of US adults; hyperlipidemia similarly prevalent — massive population
Implementation Speed 4 Policy changes are slow; surveillance data informs but does not immediately change practice
Evidence Strength 4 Ecological design; no individual-level data; cannot control for confounders at population level

Key quantitative result: Mortality "rose substantially" with "marked disparities" — specific rates not extractable from abstract. Main limitation: Ecological fallacy risk; no causal inference; projections depend on trend assumptions that may not hold. Equity implications: Explicitly identifies racial/ethnic mortality disparities — directly equity-relevant; findings call for targeted prevention in underserved communities. Evidence Maturity: Exploratory ✓


Article 14 — Wannaphut et al. — TP53-mutated AML immunotherapy review (PMID: 42966670)

Immunotherapy in TP53-mutated AML | Narrative review

Dimension Score Rationale
Scientific Novelty 5 TP53-mutated AML immunotherapy is an active area; this review synthesizes the landscape but does not add primary data
Clinical Relevance 6 TP53-mutated AML is a high-risk subtype with poor outcomes; synthesizing the immunotherapy landscape has real clinical value
Population Reach 5 TP53 mutations in AML ~8–12% of cases; high unmet need
Implementation Speed 3 Strategies discussed are largely investigational
Evidence Strength 3 Narrative review — no systematic methodology; synthesis quality depends on author selection

Main limitation: Narrative review subject to selection bias; no quantitative synthesis; no primary data. Equity implications: AML disproportionately affects older adults; access to novel immunotherapy trials is limited outside academic centers. Evidence Maturity: Exploratory ✓


Article 15 — Silva et al. — Salivary FTIR spectroscopy review (PMID: 42966635)

Salivary ATR-FTIR for systemic diseases | Scoping review

Dimension Score Rationale
Scientific Novelty 5 Non-invasive salivary diagnostics is appealing; FTIR for systemic disease detection is emerging
Clinical Relevance 4 Promising concept but no validated clinical application yet
Population Reach 7 Systemic diseases are ubiquitous; non-invasive salivary testing could have broad reach if validated
Implementation Speed 2 Substantial standardization, validation, and regulatory work needed
Evidence Strength 3 Scoping review; no external validation in primary studies; high heterogeneity

Main limitation: No standardized protocols; absence of true external validation; clinical translation timeline is long. Equity implications: Non-invasive saliva-based testing could democratize diagnostics if validated; currently academic/research only. Evidence Maturity: Exploratory ✓


Article 16 — Dong et al. — Multi-omics PTM profiling in CRC (PMID: 42966632)

Post-translational modifications in CRC RNA-binding proteins | Multi-omics study

Dimension Score Rationale
Scientific Novelty 6 PTM profiling of RNA-binding proteins in CRC is a less-explored angle; FLNA as a multi-PTM candidate is novel
Clinical Relevance 4 Exploratory molecular target; very early stage
Population Reach 6 CRC is the third most common cancer globally
Implementation Speed 2 Early discovery phase; many steps before clinical relevance
Evidence Strength 4 Multi-omics is methodologically sound; medium confidence; abstract-only; no functional validation described

Main limitation: Purely computational/correlative; FLNA's functional role in CRC not established; medium classification confidence. Evidence Maturity: Exploratory ✓


Article 17 — Niss et al. — CRF2 agonism in preclinical obesity (PMID: 42966498) ⚪

UCN2 analogues for obesity | Preclinical animal study

Dimension Score Rationale
Scientific Novelty 7 CRF2 agonism as a muscle-preserving obesity treatment is mechanistically novel and differentiated from GLP-1 class
Clinical Relevance 3 Animal study only; cannot exceed 5 per rules; muscle-preserving obesity treatment is a real unmet need
Population Reach 8 Obesity affects 40%+ of US adults; muscle-wasting on GLP-1 therapy is an emerging concern
Implementation Speed 2 Preclinical; regulatory pathway, human trials, and safety data needed
Evidence Strength 4 Well-designed preclinical study; animal-to-human translation uncertain

Main limitation: Animal model only; long translation path; GLP-1 combination not tested in humans; abstract-only. Equity implications: Novel obesity pharmacotherapy could benefit underserved populations if cost-accessible. Evidence Maturity: Exploratory ✓


Article 18 — Su et al. — M1 macrophage nanoplatform for solid tumors (PMID: 42966454) ⚪

Nanoimmunotherapy via ASNS-mTOR disruption | Preclinical

Dimension Score Rationale
Scientific Novelty 7 Macrophage membrane camouflage + metabolic-immune dual targeting is a creative and novel approach
Clinical Relevance 3 Preclinical; cannot exceed 5 per rules
Population Reach 6 Solid tumors broadly; no specific cancer type specified
Implementation Speed 2 Early preclinical; manufacturing complexity is high
Evidence Strength 4 Preclinical in vitro + xenograft; no syngeneic immunocompetent model described

Main limitation: Preclinical only; xenograft models don't fully capture immune context; manufacturability not addressed. Evidence Maturity: Exploratory ✓


Article 19 — Chandel et al. — SGLT2i genitourinary infections review (PMID: 42966404)

SGLT2 inhibitor infection risk | Narrative review

Dimension Score Rationale
Scientific Novelty 3 Well-established side effect profile; review adds little new insight
Clinical Relevance 6 Clinically useful to confirm manageable infection risk and drug interaction patterns for prescribers
Population Reach 8 SGLT2 inhibitors prescribed to millions globally for diabetes and heart failure
Implementation Speed 7 Guides current prescribing; no adoption barrier
Evidence Strength 3 Narrative review; subject to selection bias; no meta-analysis

Main limitation: Narrative review; no systematic methodology; established knowledge base limits novelty. Evidence Maturity: Exploratory ✓


Article 20 — Mehrabi et al. — MYBL2 biomarker in LSCC (PMID: 42966320)

ML-identified MYBL2 as LSCC biomarker | Computational study

Dimension Score Rationale
Scientific Novelty 6 Integration of single-cell + bulk RNA-seq + ML for LSCC biomarker discovery is methodologically current
Clinical Relevance 4 Computational discovery; no clinical validation
Population Reach 4 LSCC ~13,000 US cases/year; relatively narrow
Implementation Speed 2 Computational discovery stage; biomarker validation path is long
Evidence Strength 4 Computational methodology sound; medium confidence; no prospective validation; abstract-only

Evidence Maturity: Exploratory ✓


Article 21 — Park et al. — Mitochondrial transfer in NK cells (PMID: 42966058) ⚪

Mitochondria-boosted NK cells vs. tumors | Preclinical

Dimension Score Rationale
Scientific Novelty 7 Mitochondrial transfer to enhance NK cell immunotherapy is mechanistically innovative and biologically elegant
Clinical Relevance 3 Preclinical; cannot exceed 5 per rules; but NK cell therapy is an active clinical development area
Population Reach 6 NK cell therapies being developed broadly across cancers
Implementation Speed 2 Complex manufacturing challenge; no human data
Evidence Strength 4 In vitro + xenograft; promising but standard early-stage design

Main limitation: Xenograft models lack intact immune system; manufacturing scalability of mitochondria transfer not addressed; abstract-only. Evidence Maturity: Exploratory ✓


Article 22 — Schumann et al. — AI in axial spondyloarthritis imaging (PMID: 42966032)

AI for SpA imaging | Narrative review

Dimension Score Rationale
Scientific Novelty 5 AI in musculoskeletal imaging is a broad field; SpA-specific review is useful but not groundbreaking
Clinical Relevance 6 SpA diagnosis is often delayed by years; AI matching expert readers with external validation is clinically meaningful
Population Reach 6 Axial SpA affects ~0.5–1% of adults globally — a substantial population with significant diagnostic delay
Implementation Speed 5 Some models appear ready for prospective evaluation; regulatory pathway needed
Evidence Strength 4 Narrative review; external validation mentioned for some models but review-level synthesis limits confidence

Evidence Maturity: Exploratory ✓


Article 23 — Wang et al. — Single-cell AST imaging (PMID: 42965887)

Rapid phenotypic antimicrobial susceptibility testing | In vitro method study

Dimension Score Rationale
Scientific Novelty 7 Single-cell morphodynamic imaging for rapid AST capturing heterogeneity is genuinely novel and technically impressive
Clinical Relevance 3 In vitro only; but rapid AST is a major antimicrobial stewardship need
Population Reach 7 Antimicrobial resistance is a global health threat affecting all populations
Implementation Speed 3 Requires specialized imaging hardware and clinical validation; medium-term path
Evidence Strength 5 In vitro validation study; rigorous for its stage; no clinical sample validation described

Main limitation: In vitro only; no clinical sample validation; hardware requirements unclear for widespread deployment. Evidence Maturity: Exploratory ✓


Article 24 — Zheng et al. — MAP7D2 knockdown in LUAD (PMID: 42965843) ⚪

MAP7D2 silencing enhances T-cell response in lung cancer | Preclinical

Dimension Score Rationale
Scientific Novelty 6 MAP7D2 as an immune modulator in LUAD is relatively unexplored; syngeneic model with CD8+ mechanistic link is methodologically appropriate
Clinical Relevance 3 Animal study; cannot exceed 5
Population Reach 7 Lung adenocarcinoma is a major global cancer burden
Implementation Speed 2 Early preclinical discovery; translation path is long
Evidence Strength 4 Syngeneic immunocompetent model is a strength; no human validation

Evidence Maturity: Exploratory ✓


Article 25 — Thakur et al. — mRNA-CRISPR delivery for choroidal melanoma (PMID: 42965688) 🟡

Gene editing nanodelivery in choroidal melanoma | Preclinical narrative review

Dimension Score Rationale
Scientific Novelty 6 Dual-vector mRNA-CRISPR for ocular melanoma is novel in concept; review of preclinical field adds synthesis value
Clinical Relevance 3 Narrative review of preclinical data; rare disease with high unmet need
Population Reach 3 Choroidal melanoma ~2,500 US cases/year; very rare but high unmet need justifies attention
Implementation Speed 2 Preclinical stage; complex regulatory, manufacturing, and ocular delivery challenges
Evidence Strength 3 Narrative review of preclinical studies; no new primary data

Evidence Maturity: Exploratory ✓


Article 26 — Ernste et al. — Arrayed CRISPR T-cell screening in CLL (PMID: 42965525)

CRISPR screening platform for T-cell engager combinations | Methods/Lab

Dimension Score Rationale
Scientific Novelty 7 Autologous patient-matched T-cell CRISPR screening for combination target prioritization is a genuinely enabling platform technology
Clinical Relevance 3 In vitro platform; no clinical data; long path to patient benefit
Population Reach 5 CLL is common; broad applicability of platform beyond CLL is possible
Implementation Speed 2 Platform technology; requires specialized expertise and patient sample acquisition
Evidence Strength 4 In vitro lab study; platform validation appropriate for stage; no clinical correlation

Evidence Maturity: Exploratory ✓


Article 27 — Mino-León et al. — Polypharmacy and GFR in older adults (PMID: 42965503)

Polypharmacy and reduced GFR in older hypertensive men | Cross-sectional

Dimension Score Rationale
Scientific Novelty 4 Polypharmacy-kidney risk link is established; gender-stratified hypertension interaction adds some nuance
Clinical Relevance 6 Directly actionable: medication review in hypertensive older men could reduce renal decline
Population Reach 7 Polypharmacy in older adults is extraordinarily common; hypertension prevalence is high
Implementation Speed 7 Medication review/deprescribing is immediately actionable by geriatricians and primary care
Evidence Strength 4 Cross-sectional; cannot establish causality; abstract-only; Mexico-based cohort limits generalizability

Key quantitative result: Progressive dose-dependent GFR reduction with number of drugs; specific ORs not reported in abstract. Equity implications: Older men in Latin American settings are explicitly studied — underrepresented in many polypharmacy studies; relevant for equity in aging care. Evidence Maturity: Exploratory ✓


Article 28 — Dong et al. — Multi-omics PTM profiling in CRC (PMID: 42966632)

(Already scored as Article 16 above)


Phase 3 Ranking

Conflict/Tension Note

Two articles in this batch touch on potentially conflicting narratives around treatment intensification in oligoprogressive NSCLC: Article 4 (Massalha et al.) synthesizes observational evidence supporting local ablation + IO continuation, while clinical trial evidence supporting this strategy is absent. This tension between the mechanistic rationale and the quality of supporting data is important for practicing oncologists to recognize.

Additionally, the batch contains multiple exploratory preclinical articles flagged with encouraging framing — these should not be interpreted as near-term clinical advances. The evidence base overall is moderate, with no high-priority articles in this run.


Composite Impact Score Computation

Rank Article (PMID) Clinical Relevance (30%) Population Reach (25%) Scientific Novelty (20%) Implementation Speed (15%) Evidence Strength (10%) Composite Triage Score Priority Flag
1 Massalha et al. — LAT in oligoprogressive NSCLC (42965526) 7 7 6 6 5 6.50 7 ⬜
2 Puccini et al. — PROSIT/IE signature CRC (42966319) 7 6 7 5 7 6.50 7 ⬜
3 Yang et al. — GLP-1 RA in MASLD (42966342) 6 8 6 5 5 6.25 6 ⬜
4 Haber et al. — Low-dose alteplase in PE (42966650) 7 6 5 6 4 5.95 6 ⬜
5 Mino-León et al. — Polypharmacy and GFR (42965503) 6 7 4 7 4 5.75 6 ⬜
6 Goldman — DSRCT target atlas (42966626) 5 3 7 3 5 4.80 6 🟡
7 Chen et al. — FFL in DKD (42966155) 6 7 6 4 5 5.80 7 ⬜
8 Niss et al. — CRF2 agonism/obesity (42966498) 3 8 7 2 4 4.90 5 ⚪
9 Wang et al. — Rapid AST imaging (42965887) 3 7 7 3 5 4.90 5 ⬜
10 Khan et al. — HTN/hyperlipidemia mortality (42966230) 5 9 4 4 4 5.35 6 ⬜
11 Schumann et al. — AI in SpA imaging (42966032) 6 6 5 5 4 5.35 5 ⬜
12 Chandel et al. — SGLT2i infections (42966404) 6 8 3 7 3 5.55 5 ⬜
13 Vrancianu et al. — Raman spectroscopy glioma (42966518) 5 4 6 3 5 4.70 6 ⬜
14 John et al. — CHD gut microbiome (42966652) 5 4 6 5 5 5.00 6 ⬜
15 Kajiura et al. — Japan CGP reference (42965781) 5 6 5 6 6 5.50 7 ⬜
16 Su et al. — M1 nanoplatform immunotherapy (42966454) 3 6 7 2 4 4.35 5 ⚪
17 Wannaphut et al. — TP53-AML immunotherapy (42966670) 6 5 5 3 3 4.70 5 ⬜
18 Park et al. — Mitochondrial transfer NK cells (42966058) 3 6 7 2 4 4.35 5 ⚪
19 Choi & Lee — KMT2A-r AML (42966630) 5 4 6 3 4 4.55 6 ⬜
20 Zheng et al. — MAP7D2 in LUAD (42965843) 3 7 6 2 4 4.35 5 ⚪
21 Ernste et al. — CRISPR screening CLL (42965525) 3 5 7 2 4 4.10 5 ⬜
22 Dong et al. — PTM profiling CRC (42966632) 4 6 6 2 4 4.40 5 ⬜
23 Greathouse et al. — HFNC and dysphagia (42966646) 6 5 4 7 3 5.00 6 ⬜
24 Adams et al. — HAA in ICU (42966645) 5 5 3 6 3 4.45 6 ⬜
25 Mehrabi et al. — MYBL2 in LSCC (42966320) 4 4 6 2 4 4.00 5 ⬜
26 Thakur et al. — CRISPR choroidal melanoma (42965688) 3 3 6 2 3 3.50 5 🟡
27 Silva et al. — Salivary FTIR review (42966635) 4 7 5 2 3 4.35 5 ⬜
28 Wannaphut et al. — TP53-AML (42966670) (duplicate entry — see #17) — — — — — — — —

Tie-Breaking Note: Articles 1 and 2 (Rank 1 & 2)

Both Massalha et al. and Puccini et al. score 6.50. Per tie-breaking rules, Clinical Relevance is equal (both 7). Evidence Strength decides: Puccini et al. scores 7 (prospective trial-embedded design) vs. Massalha et al. 5 (observational meta-analysis). Therefore, Puccini et al. — PROSIT ranks #1.


Final Ranked Table

Rank Article Impact Score Clin. Rel. Pop. Reach Novelty Impl. Speed Evid. Strength Triage Score Study Design Flag
1 Puccini et al. — IE signature in stage II CRC (PROSIT) 6.50 7 6 7 5 7 7 Prospective trial correlative ⬜
2 Massalha et al. — LAT in oligoprogressive NSCLC 6.50 7 7 6 6 5 7 Systematic review/meta-analysis ⬜
3 Chen et al. — FFL supplement in DKD 5.80 6 7 6 4 5 7 Proof-of-concept RCT + preclinical ⬜
4 Yang et al. — GLP-1 RA in MASLD 6.25 6 8 6 5 5 6 Propensity-matched cohort + mouse ⬜
5 Haber et al. — Low-dose alteplase in PE 5.95 7 6 5 6 4 6 Retrospective cohort ⬜
6 Chandel et al. — SGLT2i infection risk 5.55 6 8 3 7 3 5 Narrative review ⬜
7 Mino-León et al. — Polypharmacy & GFR 5.75 6 7 4 7 4 6 Cross-sectional ⬜
8 Khan et al. — HTN/hyperlipidemia mortality trends 5.35 5 9 4 4 4 6 Ecological time-trend ⬜
9 Kajiura et al. — Japan CGP reference 5.50 5 6 5 6 6 7 Nationwide retrospective cohort ⬜
10 Schumann et al. — AI in SpA imaging 5.35 6 6 5 5 4 5 Narrative review ⬜
11 John et al. — CHD gut microbiome 5.00 5 4 6 5 5 6 Prospective matched cohort (2°) ⬜
12 Greathouse et al. — HFNC and dysphagia 5.00 6 5 4 7 3 6 Retrospective chart audit ⬜
13 Goldman — DSRCT target atlas 4.80 5 3 7 3 5 6 Multi-cohort transcriptomic 🟡
14 Niss et al. — CRF2 agonism/obesity 4.90 3 8 7 2 4 5 Preclinical animal study ⚪
15 Wang et al. — Rapid AST imaging 4.90 3 7 7 3 5 5 In vitro method validation ⬜
16 Wannaphut et al. — TP53-AML immunotherapy 4.70 6 5 5 3 3 5 Narrative review ⬜
17 Vrancianu et al. — Raman spectroscopy glioma 4.70 5 4 6 3 5 6 Systematic review ⬜
18 Adams et al. — HAA in ICU 4.45 5 5 3 6 3 6 Retrospective record review ⬜
19 Dong et al. — PTM profiling in CRC 4.40 4 6 6 2 4 5 Multi-omics profiling ⬜
20 Choi & Lee — KMT2A-r AML 4.55 5 4 6 3 4 6 Retrospective transcriptomic ⬜
21 Su et al. — M1 nanoplatform 4.35 3 6 7 2 4 5 Preclinical nanotherapy ⚪
22 Park et al. — Mitochondrial transfer NK 4.35 3 6 7 2 4 5 Preclinical in vitro/xenograft ⚪
23 Silva et al. — Salivary FTIR review 4.35 4 7 5 2 3 5 Scoping review ⬜
24 Zheng et al. — MAP7D2 in LUAD 4.35 3 7 6 2 4 5 Preclinical/syngeneic mouse ⚪
25 Ernste et al. — CRISPR screening CLL 4.10 3 5 7 2 4 5 Lab methods/protocol ⬜
26 Mehrabi et al. — MYBL2 in LSCC 4.00 4 4 6 2 4 5 Computational biomarker study ⬜
27 Thakur et al. — CRISPR choroidal melanoma 3.50 3 3 6 2 3 5 Narrative review (preclinical) 🟡

Rank 1 Justification: Puccini et al. (PROSIT) earns the top ranking by combining a methodologically rigorous, prospective trial-embedded design (TOSCA phase III) with a clinically urgent question. Stage II colorectal cancer adjuvant chemotherapy decision-making remains one of oncology's most contested gray zones — pathological risk stratification alone is insufficient, and most molecular signatures have not been tested in prospective settings. The finding that an Immune Exclusion signature predicts significantly shorter DFS, independent of MSI status and tumor sidedness, directly addresses a gap that could influence treatment decisions for tens of thousands of patients annually. The evidence strength score of 7 reflects the quality of the design, not a claim of definitive practice change, and the main uncertainty is the absence of full-text access to confirm sample size, follow-up duration, and signature assay details.

Why it matters: Identifying which stage II colon cancer patients are truly high-risk — before recurrence, not after — is the difference between cure and death for some patients. An immune signature that predicts worse outcomes independently of known prognostic factors could be the missing tool that makes that call more precisely.


Deep dive 1 Immune Exclusion Signature in Stage II Colon Cancer PMID 42966319 ↗


[HOOK]

Every year, tens of thousands of people have their colon cancer removed and are told it's stage II — technically localized, theoretically curable. But some of those patients will relapse within a few years, and we often can't tell in advance which ones. The difference between getting chemotherapy and not getting it after surgery can mean the difference between relapse and long-term survival. And right now, doctors are making that call without the full picture.

[THE DISCOVERY]

Researchers embedded a molecular profiling study — called PROSIT — inside a large phase III clinical trial of stage II colon cancer patients. Using whole-transcriptome profiling on tumor tissue, they identified what they call an "Immune Exclusion" signature: a molecular pattern that reflects whether the immune system is being blocked from entering the tumor. Patients whose tumors carried this signature had significantly shorter disease-free survival. Critically, this association held up even after accounting for two of the field's most important prognostic variables — microsatellite instability status, which reflects a tumor's DNA repair capacity, and tumor location on the left versus right side of the colon. In other words, the immune exclusion signal was adding information that existing markers weren't already capturing.

[THE SCIENCE BEHIND IT]

The PROSIT study is embedded within TOSCA — a genuine phase III randomized trial — which is a methodological advantage most transcriptomic studies can't claim. Instead of analyzing tumor samples collected opportunistically or retrospectively from disparate archives, the researchers had access to a prospective, protocol-driven cohort. Transcriptomic profiling across the whole genome allows for discovery of gene expression patterns that aren't visible with targeted assays. The study adjusted for MSI status and tumor sidedness — both of which are now standard prognostic and predictive considerations in colon cancer — meaning the IE signature is not simply a proxy for something already in clinical use. The main limitation is that full-text data has not been reviewed for this analysis: sample size, length of follow-up, the specific platform used to measure the IE signature, and the magnitude of the survival difference are not confirmed from the abstract alone.

[WHO THIS HELPS]

This study is directly relevant to the group of patients arguably most underserved by current colon cancer staging: people diagnosed with high-risk stage II disease who are MSS — microsatellite stable — meaning they don't get the immune checkpoint benefit, and whose tumors appear confined to the colon wall but carry features that suggest biology isn't as favorable as the stage implies. These patients and their oncologists are navigating a genuine therapeutic gray zone. The immune exclusion signature could help identify those who need more aggressive adjuvant treatment — before recurrence, not after.

[THE REAL-WORLD IMPACT]

If validated, this signature could be integrated into post-surgical molecular workup for high-risk stage II colon cancer — either as a standalone test or as part of an existing multi-gene panel. Oncologists would have one more piece of molecular evidence to support or refute the decision to recommend six months of chemotherapy. In a best-case scenario, this could reduce both undertreatment in high-risk patients and overtreatment in those who don't need it. Realistically, implementation would require commercial assay development, prospective validation in independent cohorts, and eventual integration into clinical guidelines — a process that typically takes five to ten years.

[WHAT WE STILL DON'T KNOW]

The central uncertainty is whether the Immune Exclusion signature is independently actionable — meaning, does treating IE-positive patients more aggressively actually improve their outcomes, or does knowing their risk simply tell us bad news without a way to change it? There's also the question of whether therapies that modulate the tumor immune microenvironment — such as checkpoint inhibitors, which are currently studied more in MSI-high patients — could potentially benefit IE-positive, MSS-high-risk stage II patients. That would require its own clinical trial. Additionally, the magnitude of the survival difference, the assay's reproducibility across labs, and cost-effectiveness for broader clinical deployment all remain to be established.

[LIKELIHOOD OF MAKING A DIFFERENCE]

  • Scientific Confidence: Moderate — prospective trial-linked design is a strength, but independent replication has not been reported
  • Translation Speed: 5–10 years for routine clinical integration
  • Barrier Analysis:
    • Regulatory: Transcriptomic signature requires IVD clearance; path is established but slow
    • Reimbursement: Multi-gene tumor signatures face payer scrutiny; clinical utility evidence required
    • Cost: Whole-transcriptome profiling is expensive; targeted panel-based implementation would be needed
    • Infrastructure: Requires pathology lab integration and bioinformatics support
    • Equity: Patients at community hospitals and in low-resource settings are unlikely to access this test early; academic center concentration is likely in the near term

[CALL TO ACTION / CLOSING]

We've had the surgery. We've read the pathology report. Now the PROSIT study tells us the tumor's immune landscape may be carrying information we haven't been listening to — and that listening more carefully could change who we treat and who we watch. The next step is independent validation, and that work should start now.